- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01202253
Early Clinical Experience With Anidulafungin In Patients With Liver Disease In The United Kingdom
March 25, 2014 updated by: Pfizer
A Study To Describe The Early Clinical Experience With Anidulafungin In Patients With Liver Disease At King's College Hospital NHS Trust, London
The purpose of this study is to describe the real world effectiveness of anidulafungin in clinical practice in a large Liver Unit in the United Kingdom.
Study Overview
Detailed Description
All subjects that have been treated with Anidulafungin according to its licence during the period of July 2009 and September 2010 will be included.
Study Type
Observational
Enrollment (Actual)
50
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
London, United Kingdom, SE5 9RS
- Pfizer Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Subjects admitted with candidiasis infections to the Liver Unit at King's College Hospital (United Kingdom) who are prescribed anidulafungin.
Description
Inclusion Criteria:
- Subjects who have been prescribed anidulafungin between 1st July 2009 and 30th September 2010.
Patients admitted to specialist liver unit wards and the Liver Intensive Therapy Unit during this period
Exclusion Criteria:
- Patients who participated in any interventional clinical trial during this episode of sepsis.
Patients who received anidulafungin for infection prophylaxis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Anidulafungin
|
A single 200 mg loading dose should be administered on Day 1, followed by 100 mg daily thereafter.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Favorable Outcome
Time Frame: Day 28 post-treatment
|
Favorable outcome was defined as favorable clinical response and documented or presumed microbial eradication (two negative follow-up blood cultures for bloodstream infections or a successful clinical response without follow-up cultures for other infections).
Favorable clinical response was defined as clinical resolution of signs and symptoms of infection and no need to change or add to antifungal therapy, or transition to oral antifungal to complete therapy.
|
Day 28 post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Unfavorable Outcome
Time Frame: Day 28 post-treatment
|
Unfavorable outcome was defined as the need to change to another antifungal agent because of lack of clinical response or death due to the antifungal infection or microbiologic persistence of the fungus or superinfection with a new Candida, Aspergillus or other fungal strain occurring at least 3 days and up to 14 days of anidulafungin therapy, or a lack of follow up data about clinical and microbiologic responses at the end of anidulafungin therapy.
|
Day 28 post-treatment
|
Percentage of Participants Who Died Due to All Causes
Time Frame: Baseline up to Day 28 post-treatment
|
Death due to all causes included death attributable to fungal infection, death unrelated to fungal infection and death due to multiple causes.
|
Baseline up to Day 28 post-treatment
|
Percentage of Participants With Death Attributable to Fungal Infection
Time Frame: Baseline up to Day 28 post-treatment
|
Baseline up to Day 28 post-treatment
|
|
Percentage of Participants With Death Unrelated to Fungal Infection
Time Frame: Baseline up to Day 28 post-treatment
|
Baseline up to Day 28 post-treatment
|
|
Percentage of Participants With Favorable Clinical Response
Time Frame: Day 28 post-treatment
|
Favorable clinical response was defined as clinical resolution of signs and symptoms of infection and no need to change or add to antifungal therapy, or transition to oral antifungal to complete therapy.
|
Day 28 post-treatment
|
Percentage of Participants With Lack of Clinical Response
Time Frame: Day 28 post-treatment
|
Favorable clinical response was defined as clinical resolution of signs and symptoms of infection and no need to change or add to antifungal therapy, or transition to oral antifungal to complete therapy.
|
Day 28 post-treatment
|
Percentage of Participants Requiring Change or Additional Antifungal Therapy
Time Frame: Baseline up to Day 28 post-treatment
|
Lower limit of confidence interval was reported as 0 if the same was calculated as less than 0 by standard calculations (outside the valid range of 0 to 100).
|
Baseline up to Day 28 post-treatment
|
Percentage of Participants With Oral Antifungal Started to Complete Therapy
Time Frame: Baseline up to Day 28 post-treatment
|
Baseline up to Day 28 post-treatment
|
|
Percentage of Participants With Documented Eradication of Infecting Species
Time Frame: Baseline
|
Documented microbial eradication was defined as 2 negative follow-up blood cultures for bloodstream infections.
|
Baseline
|
Percentage of Participants With Resolution of Signs of Infection According to Ultrasound Scan Results
Time Frame: Baseline up to Day 28 post-treatment
|
An ultrasound scan was performed and the resultant scan was reviewed for the presence of the infection as per investigator's discretion.
|
Baseline up to Day 28 post-treatment
|
Percentage of Participants With Resolution of Signs of Infection According to Computerized Tomography (CT) Scan Results
Time Frame: Baseline up to Day 28 post-treatment
|
A CT scan was performed and the resultant scan was reviewed for the presence of the infection as per investigator's discretion.
|
Baseline up to Day 28 post-treatment
|
Percentage of Participants With Abnormal Results for Liver Function at Initiation of Drug Therapy
Time Frame: Baseline
|
Percentage of participants with abnormal liver function results were based on 4 liver function variables- bilirubin, aspartate transaminase, alkaline phosphatase and gamma glutamyl transferase.
Normal reference ranges of these variables are: plasma bilirubin: 3-17 micromoles/L or 2.5-10 mg/L for adults; aspartate transaminase: 6-34 International Units/Liter (IU/L) for females and 8-40 IU/L for males; alkaline phosphatase: 5-38 IU/L for females and 10-50 IU/L for males; gamma glutamyl transferase: 7-32 IU/L for females and 11-50 IU/L for males.
Upper limit of confidence interval was reported as 100 if the same was calculated as greater than 100 by standard calculations (outside the valid range of 0 to 100).
|
Baseline
|
Percentage of Participants With Abnormal Results for Liver Function at End of Drug Therapy
Time Frame: Day 28 post-treatment
|
Percentage of participants with abnormal liver function results were based on 4 liver function variables- bilirubin, aspartate transaminase, alkaline phosphatase and gamma glutamyl transferase.
Normal reference ranges of these variables are: plasma bilirubin: 3-17 micromoles/L or 2.5-10 mg/L for adults; aspartate transaminase: 6-34 IU/L for females and 8-40 IU/L for males; alkaline phosphatase: 5-38 IU/L for females and 10-50 IU/L for males; gamma glutamyl transferase: 7-32 IU/L for females and 11-50 IU/L for males.
|
Day 28 post-treatment
|
Percentage of Participants With Liver Function Test Results at Least Twice the Baseline Value During Period of Drug Therapy
Time Frame: Baseline up to Day 28 post-treatment
|
Percentage of participants with liver function test results at least twice the baseline value during period of drug therapy was calculated for the liver function variables, bilirubin, aspartate transaminase, alkaline phosphatase and gamma glutamyl transferase.
|
Baseline up to Day 28 post-treatment
|
Percentage of Participants With Creatinine Clearance at Least Twice the Baseline Value During Period of Drug Therapy
Time Frame: Baseline up to Day 28 post-treatment
|
Baseline up to Day 28 post-treatment
|
|
Percentage of Participants Admitted to Liver Intensive Therapy Unit (LITU)
Time Frame: Baseline
|
Baseline
|
|
Duration of Stay at Liver Intensive Therapy Unit (LITU)
Time Frame: Baseline up to Day 28 post-treatment
|
Baseline up to Day 28 post-treatment
|
|
Percentage of Participants With Absolute Neutrophil Count Less Than 500 Per Cubic Millimeter (/mm^3) and Greater Than or Equal to 500 /mm^3
Time Frame: Baseline
|
Lower limit of confidence interval was reported as 0 if the same was calculated as less than 0 and upper limit of confidence interval was reported as 100 if the same was calculated as greater than 100, by standard calculations (outside the valid range of 0 to 100).
|
Baseline
|
Percentage of Participants With Concomitant Bacterial or Viral Infection
Time Frame: Baseline
|
Upper limit of confidence interval was reported as 100 if the same was calculated as greater than 100 by standard calculations (outside the valid range of 0 to 100).
|
Baseline
|
Percentage of Participants Prescribed With Systemic Antifungal Within 30 Days Before Study Start
Time Frame: Baseline
|
Lower limit of confidence interval was reported as 0 if the same was calculated as less than 0 by standard calculations (outside the valid range of 0 to 100).
|
Baseline
|
Dose Changes for Immunosuppressant Drugs
Time Frame: Baseline up to Day 28 post-treatment
|
Baseline up to Day 28 post-treatment
|
|
Percentage of Participants With Probable or Proven Fungal Infection at the Initiation of Drug Therapy
Time Frame: Baseline
|
Baseline
|
|
Percentage of Participants With Documented Body Temperature Above 38.0 Degree Celsius or Below 36.0 Degree Celsius Within 24 Hour Period Prior to Initiation of Drug Therapy
Time Frame: Baseline
|
Lower limit of confidence interval was reported as 0 if the same was calculated as less than 0 and upper limit of confidence interval was reported as 100 if the same was calculated as greater than 100, by standard calculations (outside the valid range of 0 to 100).
|
Baseline
|
Percentage of Participants With Systolic Blood Pressure More Than 2 Standard Deviations Below the Mean for Age Recorded Within 24 Hour Period Prior to Initiation of Drug Therapy
Time Frame: Baseline
|
Lower limit of confidence interval was reported as 0 if the same was calculated as less than 0 by standard calculations (outside the valid range of 0 to 100).
|
Baseline
|
Number of Participants With Infection Sites as Per Microbiological Analysis
Time Frame: Baseline
|
Infection sites included blood, chest, urinary tract, intra-abdominal, bile duct, liver, kidney, mouth and esophagus.
|
Baseline
|
Number of Participants With Infection Sites as Per Ultrasound Scan and Computerized Tomography (CT) Scan
Time Frame: Baseline
|
Baseline
|
|
Infecting Organisms by Species
Time Frame: Baseline up to Day 14 post-treatment
|
Baseline up to Day 14 post-treatment
|
|
Percentage of Participants With Prior Colonization With Candida by Species
Time Frame: Baseline
|
Lower limit of confidence interval was reported as 0 if the same was calculated as less than 0 by standard calculations (outside the valid range of 0 to 100).
|
Baseline
|
Percentage of Participants With Prior Colonization With Candida by Colonization Index
Time Frame: Baseline
|
Baseline
|
|
Percentage of Participants With Other Prior Fungal Infection by Species and Colonization Index
Time Frame: Baseline
|
Baseline
|
|
Number of Participants Who Received Water-based and Ethanol-based Formulation
Time Frame: Baseline
|
Baseline
|
|
Percentage of Participants Who Received Water-based and Ethanol-based Formulation
Time Frame: Baseline
|
Baseline
|
|
Percentage of Participants Who Received 200 mg Loading Dose
Time Frame: Day 1
|
Day 1
|
|
Percentage of Participants Who Received 100 mg Dose on Day 2
Time Frame: Day 2
|
Day 2
|
|
Percentage of Participants Who Received 200 mg Dose on Day 1 and 100 mg for All Subsequent Doses
Time Frame: Baseline up to Day 28 post-treatment
|
Baseline up to Day 28 post-treatment
|
|
Number of Participants With Other Dosing Patterns
Time Frame: Baseline up to Day 28 post-treatment
|
The other dosing patterns for anidulafungin included any dosing pattern different from 200 mg loading dose on Day 1 followed by 100 mg doses subsequently starting from Day 2.
|
Baseline up to Day 28 post-treatment
|
Duration of Anidulafungin Therapy
Time Frame: Baseline
|
Baseline
|
|
Number of Serious Adverse Events (SAEs)
Time Frame: Baseline up to Day 28 post-treatment
|
Any untoward medical occurrence in a participant who received study treatment was considered an adverse event (AE) without regard to possibility of causal relationship.
An AE resulting in any of the following outcomes, or deemed to be significant for any other reason, was considered to be a SAE: death; initial or prolonged inpatient hospitalization; a life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
|
Baseline up to Day 28 post-treatment
|
Percentage of Participants With One or More Drug-related Serious Adverse Events (SAEs)
Time Frame: Baseline up to Day 28 post-treatment
|
Baseline up to Day 28 post-treatment
|
|
Number of Participants With Different Types of Drug-related Serious Adverse Events
Time Frame: Baseline up to Day 28 post-treatment
|
Baseline up to Day 28 post-treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2011
Primary Completion (Actual)
May 1, 2011
Study Completion (Actual)
May 1, 2011
Study Registration Dates
First Submitted
September 13, 2010
First Submitted That Met QC Criteria
September 13, 2010
First Posted (Estimate)
September 15, 2010
Study Record Updates
Last Update Posted (Estimate)
April 16, 2014
Last Update Submitted That Met QC Criteria
March 25, 2014
Last Verified
March 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- A8851028
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Candidiasis
-
Duke UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Children's Hospital...CompletedPediatric Invasive CandidiasisUnited States, Colombia, Canada, India, Saudi Arabia, Greece, Italy, Spain
-
Centre Hospitalier Universitaire DijonCompleted
-
Robert Krause, MDCompletedInvasive Candidiasis | Pulmonary CandidiasisAustria
-
Astellas Pharma IncCompletedCandidemia | Invasive Candidiasis | Esophageal Candidiasis | Oropharyngeal CandidiasisUnited States, South Africa
-
Astellas Pharma IncCompletedCandidemia | Invasive Candidiasis | Esophageal Candidiasis | Oropharyngeal CandidiasisUnited States
-
Yung Shin Pharm. Ind. Co., Ltd.Completed
-
Duke UniversityChildren's Hospital of PhiladelphiaCompletedInvasive CandidiasisUnited States, Saudi Arabia, Greece, Spain
-
Merck Sharp & Dohme LLCTerminated
-
Hasan Al-DorziKing Fahad Medical CityCompleted
-
PfizerVicuron PharmaceuticalsCompleted
Clinical Trials on anidulafungin
-
Radboud University Medical CenterCompletedLeukemia | Leukemia, Myeloid, Acute | Myelodysplastic SyndromeNetherlands
-
National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Neutropenia | InfectionUnited States
-
Daren K. HeylandPfizer; Queen's University; The Physicians' Services Incorporated FoundationTerminatedVentilator Associated Pneumonia | Respiratory Tract InfectionCanada
-
Radboud University Medical CenterCompletedObesity MorbidNetherlands
-
PfizerTerminatedCandidiasis | Fungemia | NeutropeniaPoland, Russian Federation, France, Bosnia and Herzegovina, Italy, Slovakia
-
PfizerVicuron PharmaceuticalsCompleted
-
PfizerVicuron PharmaceuticalsCompleted
-
PfizerVicuron PharmaceuticalsCompleted
-
PfizerVicuron PharmaceuticalsCompletedNeutropeniaUnited States
-
PfizerTerminatedCandidiasis | FungemiaBelgium, United States, Canada, Switzerland, Netherlands, Bulgaria, Portugal, Romania, Russian Federation